TGTX (TG Therapeutics) LT-Debt-to-Total-Asset: 0.49 (As of Mar. 2026)

What is TG Therapeutics LT-Debt-to-Total-Asset?

TG Therapeutics TGTX +3.56% 82 LT-Debt-to-Total-Asset is 0.49 as of Mar. 2026. GuruFocus rates TGTX with a GF Score™ of 82/100 and a GF Value™ of $58.88 (Fairly Valued). The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TG Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.49.

TG Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.39) to Mar. 2026 (0.49). It may suggest that TG Therapeutics is progressively becoming more dependent on debt to grow their business.

TG Therapeutics (NAS:TGTX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TG Therapeutics LT-Debt-to-Total-Asset Related Terms

TG Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics LT-Debt-to-Total-Asset Chart

TG Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.20

0.42

0.33

0.44

0.24

TG Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.39	0.36	0.25	0.24	0.49

82GF Score

TG Therapeutics Inc TGTX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

TG Therapeutics LT-Debt-to-Total-Asset Calculation

TG Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	252.666	/	1063.253
	=	0.24

TG Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	751.735	/	1528.837
	=	0.49

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.49 mean?

TG Therapeutics (TGTX) has a LT-Debt-to-Total-Asset of 0.49 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TG Therapeutics and its competitors.

Is TG Therapeutics' LT-Debt-to-Total-Asset too high?

TG Therapeutics' current LT-Debt-to-Total-Asset is 0.49. Overall, TG Therapeutics has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does TG Therapeutics' LT-Debt-to-Total-Asset compare to HALO and KYMR?

TG Therapeutics' LT-Debt-to-Total-Asset of 0.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current LT-Debt-to-Total-Asset is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is TG Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, TG Therapeutics (TGTX) is currently considered Fairly Valued. The stock's GF Value™ is $58.88, compared to a current price of $55.21 — trading 6.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.49. TG Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For TG Therapeutics (TGTX), the current LT-Debt-to-Total-Asset is 0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (TGTX) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $55.21 is trading 6.2% below its estimated GF Value™ of $58.88. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for TGTX:

LT-Debt-to-Total-Asset: 0.49
GF Value™: $58.88 vs. price of $55.21 (6.2% below fair value)
GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies HALO KYMR PCVX IBRX IMVT PRAX PTGX CORT SYRE MIRM VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 1TGTX:Italy NKB2:Germany

Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560

Website https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

82GF Score

Get the complete analysis for TGTX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$55.21

Price

$58.88

GF Value

View TGTX Analysis

See LT-Debt-to-Total-Asset data for all stocks →